Would you offer adjuvant abemaciclib to young, premenopausal women desiring more children who meet criteria for the same based on monarchE trial?
Is there data on the long-term effects of abemaciclib on future fertility and pregnancy after its discontinuation?
Does the patient's desire for future pregnancy factor into your decision-making regarding eligibility for abemaciclib?
Community PollStarted
Do you have concerns about use of CDK4/6 inhibitors for patients desiring future pregnancy?
79 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Ohio State University
Answered on
Based on the package insert for abemaciclib, there is no reported risk of early menopause or amenorrhea. CDK4/6 inhibitors are cytostatic (by blocking the transition from G1 to S phase) and not cytotoxic, unlike alkylating chemotherapy. So, I would feel comfortable offering abemaciclib and subsequently interrupting this therapy with appropriate washouts from adjuvant endocrine therapy and abemaciclib when the patient desires pregnancy.
Join for free or sign in to see the full answer